# "Efficacy and Safety of Infliximab-biosimilar (Inflectra) Compared to Infliximab-innovator (Remicade) in Patients With Inflammatory Bowel Disease in Remission: the SIMILAR Trial"

> **NCT02452151** · PHASE4 · UNKNOWN · sponsor: **Onze Lieve Vrouwe Gasthuis** · enrollment: 300 (estimated)

## Conditions studied

- Colitis, Ulcerative
- Crohn's Disease

## Interventions

- **DRUG:** Infliximab-Biosimilar
- **DRUG:** Infliximab-Innovator

## Key facts

- **NCT ID:** NCT02452151
- **Lead sponsor:** Onze Lieve Vrouwe Gasthuis
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-08
- **Primary completion:** 2016-08
- **Final completion:** 2016-09
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2015-05-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02452151

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02452151, ""Efficacy and Safety of Infliximab-biosimilar (Inflectra) Compared to Infliximab-innovator (Remicade) in Patients With Inflammatory Bowel Disease in Remission: the SIMILAR Trial"". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02452151. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*